- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Updates in ALK+ NSCLC: ALINA Trial at ESMO 2023
Patrick Forde, MBBCh, discusses ALK rearrangement in NSCLC and highlights ALINA trial results from ESMO 2023.
EP: 1.CheckMate 77T: Perioperative Immunotherapy in Resectable NSCLC
EP: 2.Evolving NSCLC Landscape: Comparing Recent Updates in Neoadjuvant and Perioperative Immunotherapy
EP: 3.Updates in ALK+ NSCLC: ALINA Trial at ESMO 2023
EP: 4.Lessons from LIBRETTO-431 Trial in RET+ NSCLC
EP: 5.PAPILLON Trial Insights: ESMO 2023
EP: 6.Innovations Needed and Future Directions in Treatment of NSCLC
This is a video synopsis/summary of a Post Conference Perspectives involving Patrick Forde, MBBCh.
Forde discusses recent results from the ALINA trial of alectinib in early-stage ALK-positive (ALK+) non–small cell lung cancer (NSCLC). ALK alterations (fusion genes) occur in about 2% of NSCLC tumors, predominantly in younger nonsmokers. Alectinib is approved in advanced NSCLC with an ALK alteration based on improved efficacy and tolerability over crizotinib. The ALINA trial randomly assigned patients with resected stage IB to IIIA (equivalent to current stage II-IIIA) ALK+ NSCLC to either adjuvant platinum doublet chemotherapy or up to 2 years of alectinib. Alectinib significantly reduced the risks of disease recurrence or death by 76% compared with platinum doublet chemotherapy. Alectinib also markedly decreased brain metastases, which commonly occur with ALK+ NSCLC. Preliminary 3-year follow-up data suggests a benefit persisting after stopping alectinib at 2 years.
Forde states these results are a significant advance and alectinib will likely become the standard of care once approved in this setting. He notes some open questions remain regarding whether to give chemotherapy first followed by alectinib or proceed directly to alectinib, given the 5% benefit of surgery followed by adjuvant chemotherapy historically. However, either approach will provide significant benefits for patients with resected ALK+ NSCLC compared with previous options.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Integrated Care for Chronic Conditions: A Randomized Care Management Trial
December 3rd 2025The authors sought to understand the differential impact of payer-led community-based care management approaches on stakeholder-oriented outcomes for publicly insured adults with multiple chronic conditions.
Read More
Managed Care Reflections: A Q&A With A. Mark Fendrick, MD, and Michael E. Chernew, PhD
December 2nd 2025To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The December issue features a conversation with AJMC Co–Editors in Chief A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design and a professor at the University of Michigan in Ann Arbor; and Michael E. Chernew, PhD, the Leonard D. Schaeffer Professor of Health Care Policy and the director of the Healthcare Markets and Regulation Lab at Harvard Medical School in Boston, Massachusetts.
Read More
